NCT06476067Recruiting
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 21 Jun 2024
- Start date
- 1 Jan 2006
- Primary completion date
- 18 Jun 2028
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06476067
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Jan 2006 to the primary completion date, 18 Jun 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients lacking clinical information within 2 years of surgery.
Other illness
- Patients with multiple cancers.
Who the study is looking for
- Patients who had histologically confirmed ESCC.
- Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.
- Patients for whom tissue samples are available
- Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.
- Written informed consent following full study information is provided to the patient.
Age in the registry: 20 years to - · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yamanashi Universiy Coordinator of this site? Confirm its status | Chūō | Japan | Recruiting |
| Nagoya University Coordinator of this site? Confirm its status | Nagoya | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.